AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding within Google parent company Alphabet, raising $600 million to advance its ...
In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed ...
Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and ...
Isomorphic Labs, the London-based, drug discovery–focused spinout of Google AI R&D division DeepMind, today announced that it’s entered into strategic partnerships with two pharmaceutical giants, Eli ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Isomorphic Labs, a British company developing new ways ...
p-groups may be classified by splitting the groups up into classes having the same commutator relations (isoclinism classes) and then determining the non-isomorphic groups in each class. This paper ...
Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline. Isomorphic Labs, ...
The field of drug discovery has been supercharged by the capabilities of AI, which several companies have applied in various ways to turn an enormous practical problem into a tractable information ...
Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is pairing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback